An MTHFR variant, homocysteine, and cardiovascular comorand epidemiologic evidence is mixed, and the lack of clinibidity in renal disease.
than there is in the general population.
Methods.
A cross-sectional sample of 459 patients with ESRD on chronic dialysis was assessed to determine whether tHcy and A common variant of a key enzyme in homocysteine the C677T mutation are associated with CVD prevalence in multimetabolism, the C677T mutation (also known as the therple logistic regression. As CVD mortality is high, we examined molabile variant) of methylenetetrahydrofolate reducthe relationship between homozygosity and duration of dialysis.
tase (MTHFR), located on chromosome 21, is emerging
Results. Mean tHcy was higher in patients without a history as a possible genetic contributor to hyperhomocysteineof CVD (35.2 mol/L vs. 30 .4 mol/L, P ϭ 0.02). In multivariate models, CVD was negatively associated with tHcy and posimia and CVD. The C677T point mutation of MTHFR tively associated with TT genotype, male gender, and body results in a valine substitution for alanine [2] . With two mass index. Mean tHcy levels were higher among those with copies of this variant (TT), serum activity of MTHFR is the TT genotype compared with those with the CC genotype reduced to 30%, while serum activity of heterozygotes when adjusted for age, folate, creatinine, and albumin (37.9 (CT) is 65% of that of wild-type (CC) individuals [2] . mol/L vs. 31.9 mol/L, P ϭ 0.005). Among whites, the prevaEpidemiologic evidence supports an influence of C677T lence of the TT genotype was higher in those having undergone less than one year of dialysis (P ϭ 0.002).
genotype on homocysteine metabolism for those with
Conclusions. The C677T genotype of MTHFR is associated relatively reduced folate levels [3] [4] [5] , and this is mildly with CVD in ESRD and may be a more meaningful marker and less consistently so for the general population [3, 6] .
than tHcy for abnormal homocysteine metabolism in ESRD.
The C677T mutation also may influence tHcy levels in Prospective data from ongoing clinical trials are needed to ESRD, especially in those with low folate levels [7, 8] .
improve our understanding of these findings. Screening for this
The role of the C677T mutant allele in increasing the polymorphism may help guide prevention measures. risk for vascular disease was unconfirmed in large studies [3, 9] , a recent meta-analysis [6], and was not found in a study of 545 Japanese hemodialysis patients [7] . While Hyperhomocysteinemia is under intense investigation it appears that the C677T mutation of the MTHFR gene as a readily modifiable risk factor for cardiovascular dismay influence tHcy levels, especially in folate depletion, ease (CVD) in the general population and in those with its role in hyperhomocysteinemia and CVD is unclear. renal impairment. Despite homocysteine's role in vascuPatients with ESRD have levels of tHcy that are three lar pathophysiology in vitro and animal studies, clinical times those of the general population [10] . Despite a strong, positive relationship between serum creatinine and tHcy [11] , the mechanism of hyperhomocysteinemia Because patients with ESRD have a crude mortality rate of 24%, half of which is due to CVD [14] , improved  2001 by the International Society of Nephrology understanding of tHcy and cardiovascular risk may lead to for over-the-counter vitamin supplement intake. For those on hemodialysis, the following were collected: vascular the development of treatment and prevention strategies.
We undertook an investigation of tHcy and the C677T access history and predialysis and post-dialysis systolic and diastolic blood pressure (averaged over 9 treatments). mutation of MTHFR in the pathogenesis of CVD. This report is a cross-sectional analysis of baseline entry data In addition, the most recently monthly dialysis adequacy parameters were collected for all hemodialysis subjects. from a randomized prospective clinical trial of tHcy reduction in ESRD patients. The questions addressed in Adequacy parameters included Kt/V, a unit-less measure of dialysis dose, and normalized protein catabolic rate this article are as follows: (1) Is tHcy associated with CVD in this population? (2) What factors influence the (nPCR). This kinetic modeling was single-pool, variablevolume urea using predialysis and post-dialysis blood urea tHcy level? (3) Is the C677T variant of MTHFR associated with elevated tHcy, CVD, and survival on dialysis?
nitrogen (BUN) assessment. The predialysis blood sample was taken prior to the initiation of dialysis and administration of saline or heparin. The post-dialysis sample was METHODS taken from the arterial port closest to the patient using Study population the slow flow technique (within 15 to 30 seconds with the blood flow rate decreased to between 50 to 100 mL/min). This analysis represents the findings of the baseline entry exam to a clinical trial, after informed consent and Biochemical assays prior to initiation of any study procedures or treatments. The clinical trial was a randomized, standard-therapy All patients had predialysis study blood samples drawn in conjunction with routine monthly specimens. tHcy controlled study of high-dose folic acid for the reduction of tHcy with clinical outcomes as end points. We studied concentrations were determined by high-performance liquid chromatography (HPLC) of serum specimens by 459 prevalent patients with ESRD undergoing chronic dialysis treatment (430 hemodialysis and 29 peritoneal Quest Diagnostics (San Diego, CA, USA). Normal values by this method are 2.8 to 13.5 mol/L. Serum folate dialysis) at 10 affiliated nonprofit outpatient units in northern California from March 1998 to May 1999. Adult was determined using an ion capture assay that remains linear up to 20 ng/mL. Specimens with levels higher than patients who were undergoing hemodialysis or peritoneal dialysis and who were able to participate in the consent 20 ng/mL were diluted. The normal range for serum folate was 3.1 to 12.4 ng/mL. Vitamin B 12 determination process were eligible for the study. Patients who were undergoing intradialytic parenteral nutrition, anticipatwas performed using standard clinical diagnostic techniques by Quest Diagnostics. The normal range for vitaing a living-related kidney transplant, receiving an antiseizure medication, or were terminally ill were excluded min B 12 was 200 to 1100 pg/mL. Total cholesterol, albumin, urea, creatinine, pre-albumin, phosphorus, glucose, from the study. A written consent was obtained from every patient after a full explanation of the study, which and triglyceride determinations were performed at Satellite Laboratory Services, Inc., as part of the routine was approved by the Administrative Panel on Human Subjects in Medical Research of Stanford University. At monthly care. Identification of the C677T translocation was performed using HinfI digestion and polymerase the time that these data were gathered, the participants had not received instructions to change their pattern of chain reaction (PCR) amplification from specimens of peripheral blood lymphocytes as described by Frosst et folic acid or multivitamin use. CVD was defined as being present if there was a history of coronary artery intervenal [2] . PCR analysis was performed in the Molecular Diagnosis Laboratory (Department of Pathology, Stantion, myocardial infarction, stroke, transient ischemic attack, carotid end-arterectomy, or other clinical eviford University Medical Center, Palo Alto, CA, USA). dence of CVD, as documented in hospital discharge sumStatistical methods maries or history and physical examination upon admission to the dialysis unit.
Correlations between continuous variables were tested with Pearson's correlation coefficient. Chi-square tests Baseline clinical variables were collected at the time of enrollment. These included diabetes status; smoking and analysis of variance were used to test relationships concerning dichotomous variables. The Student t test was history; duration of renal replacement therapy; prescribed medication use, including dose and formulation of all vitaused for testing involving means of distributions. The distribution of genotypes was assessed for conformation min supplements; height; and dry weight (the prescribed, postdialysis weight). Race was assigned from one of the to the Hardy-Weinberg equilibrium by chi-square analysis as described by Emery [15] . Logistic regression was following categories: African American, Asian/Pacific Islander, other/multiracial, or white. Patients were assigned used to identify independent predictors of CVD and multiple linear regression was used to identify indepena separate ethnic status that included Hispanic or nonHispanic. Patients from four facilities were further asdent relationships to tHcy. All data analyses were performed using the SAS Systems version 6.1.2 software sessed for compliance with prescribed vitamin use and Characteristics by C677T mutation of cystic/hereditary/congenital (4.6%), neoplasms (0.4%), MTHFR genotype miscellaneous (2.0%), and etiology uncertain or unknown (2.2%).
There were 59 patients with two copies (TT) of the allele, 184 with one copy (CT), and 216 with the wildThe clinical characteristics of the cohort with respect to the presence of CVD are described in Table 1 . Mean type allele (CC). This distribution did not vary significantly from the expected frequencies (49.7 TT, 202.6 tHcy was significantly higher in patients without a history of CVD (35.2 mol/L Ϯ 24.0) as compared with those CT, 206.7 CC) of these genotypes based on a HardyWeinberg equilibrium ( 2 ϭ 3.89, degrees of freedom 2, with a history of CVD (30.4 mol/L Ϯ 12.9, P ϭ 0.02). Patients with CVD were of older age, smaller size, and P ϭ 0.14). There were very few copies of the thermolabile variant in nonwhite ethnic groups. Three Asian pahigher nPCR. The duration of dialysis, vitamin B 12 levels, folate levels, pre-albumin, cholesterol, creatinine, phostients, as well as one African American patient, were for Hispanics and 12.4% for non-Hispanic whites ( 2 ϭ 9.0, degrees of freedom 2, P ϭ 0.01). Table 2 shows the clinical characteristics of the three genotypes. The genotypes were similar with respect to age, age at initiation of dialysis, duration of dialysis, folate, and albumin. When adjusted for age, folate, creatinine, and albumin, tHcy levels were significantly higher in the TT group than in the CC group (39.4 mol/L in TT vs. 31.4 mol/L in CC at the Ͻ0.005 level by the Bonferroni t test for multiple comparisons). The genotypes differed are shown with standard error bars for each genotype. There were no significant differences in tHcy among the genotypes in the above-median and 32.4%, respectively, P ϭ 0.05 by the Bonferroni t test folate group (). There was an effect of genotype on tHcy in the below for multiple comparisons). This relationship persisted median folate group (P ϭ 0.01). This effect persisted when adjusting for after adjustment for age, race, and gender. The effect of age, creatinine, and albumin. The asterisk refers to significant difference compared with the CC genotype in the below median folate group at the TT genotype under conditions of below median fothe 0.05 level using the Bonferroni analysis of multiple comparisons.
late status is illustrated in Figure 1 . The study group was divided in two groups based on folate levels (above and below the median level of 17.6 mg/L). plement were at least partially compliant (taken at least Concomitant vitamin and folate use once in past 2 weeks), and 18% of patients not prescribed Of the 459 patients, 80% were prescribed a supplea folic acid-containing supplement were taking at least ment containing folic acid, vitamin B 6 , and vitamin B 12 .
one folic acid-containing supplement. Brand name, dose, At four facilities representing 206 patients, we obtained and actual dosing frequency were obtained on all 206, further concomitant vitamin information. Of these 206, and the mean total daily amounts were as follows: folic acid 0.67 mg, vitamin B 6 7.27 mg, and vitamin B 12 5.52 g. 80% of patients prescribed a folic acid-containing sup- controlling for age, race/ethnicity, gender, and diabetes). ysis of greater than one year (Fig. 2) . This was statistically b Predialysis diastolic blood pressure significant for non-Hispanic whites (25% compared with 8%, P ϭ 0.002). Among Hispanics with less than oneyear duration of dialysis, the TT genotype prevalence Prediction of tHcy was 36% compared with 20% for those with greater than one-year duration of dialysis (P ϭ 0.13). Univariate analysis of tHcy is shown in Table 3 , which presents the Pearson correlation coefficients of several clinical variables. tHcy had a strongly positive correlation DISCUSSION to creatinine and albumin and a strongly negative correIn this cross-sectional analysis of 459 dialysis patients, lation to age, folate, and daily intake of folic acid, vitamin patients with a history of CVD had lower levels of tHcy B 6 , and vitamin B 12 . There were milder associations bethan those without a history of CVD. This negative relatween tHcy and duration of dialysis, body mass index, tionship persisted in multivariate analysis when controlvitamin B 12 level, and pre-albumin.
ling for predictors of CVD, such as age, gender, and body In multiple linear models for prediction of tHcy values, mass index. However, the TT genotype was associated homozygosity for the C677T mutation, albumin, creatiwith prevalent CVD, even after adjustment for other nine, and an interaction term for folate and genotype cardiovascular risk factors, including tHcy, and was assowere strong, independent predictors. Body mass index, ciated with duration of dialysis in non-Hispanic whites. vitamin B 12 level, and folate level were weaker indepenConsistent with other investigations in the general popudent predictors. Age, gender, and actual daily intake lation and ESRD, an association of the TT genotype and amounts of folic acid, vitamin B 6 , and B 12 dropped out tHcy was found among those in the lower half of the of models.
folate distribution.
Cardiovascular disease
There are several reasonable explanations for the inverse association between tHcy and CVD and for the The presence of CVD was independently predicted association of the TT genotype with CVD observed in by gender (female protective), body mass index (negatively), predialysis diastolic blood pressure (negatively) this cross-sectional analysis. First, a single determination of tHcy in ESRD, as measured in a cross-sectional study, to CVD [18] . While in the univariate analyses in this study tHcy correlated with serum albumin, pre-albumin, may not represent lifetime tHcy exposure. During the years prior to the development of ESRD, tHcy was likely and body mass index, there was no evidence that those with CVD possessed a worse nutritional status than those lower than the tHcy measured after dialysis was initiated. Historical tHcy determinations are required to assess the without CVD. Inflammatory markers were not measured in our study. If nutritional or inflammatory status does relationship to evolving CVD. However, the presence of genetic polymorphisms, such as the C677T variant of play a role in the reverse association between tHcy and CVD prevalence, we were unable to detect it in this MTHFR, remains constant over a lifespan and can suggest a lifetime of abnormal homocysteine metabolism.
cross-sectional analysis. Fourth, the phenomenon of an established risk factor Our data support the association of the homozygous C677T variant of MTHFR and CVD. This implies that in the general population having a markedly different if not opposite pattern in ESRD is not unique to our data. C677T genotype may be a better predictor of CVD in ESRD than a single measurement of tHcy.
Blood pressure, body size, and serum cholesterol are well-established factors in the general population associSecond, methodological limitations constrain the interpretation of findings from cross-sectional analyses.
ated with increasing cardiovascular risk [19, 20] , whereas in ESRD, there is a dramatically different picture. Blood For studies of ESRD patients, this is particularly relevant due to survivor bias from high mortality rates. Survivor pressure tends to have a "U"-shaped relationship with mortality [21] , while body size and cholesterol have an bias can potentially exert a strong influence on both cross-sectional studies and clinical trials during the inverse relationship [22, 23] . This does not mean that the forces of vascular pathophysiology are different in course of dialysis, especially when patients are enrolled with varying degrees of duration of dialysis. Ideally, clini-ESRD, but suggests there are underlying factors responsible for the apparent reversal of relationships observed cal studies include patients from the same duration of dialysis cohort, that is, recent initiators and attempt to when traditional variables are analyzed in ESRD. For example, in a hypothetical model adjusting for malnutricontrol for differences in residual renal function. Survival to the clinical state of ESRD may in and of itself impart tion, the direction of the relationship of cholesterol and mortality reverses [24] . It is conceivable that cardiovasa different risk profile, as patients with chronic renal insufficiency (and possibly the most adverse homocyscular risk factors, as we understand them in the general population, behave quite differently in ESRD due to teine metabolism) succumb to CVD. Additional methodologic explanations for reversal of association include reverse causation [24] . Similar relationships may apply to tHcy as well, whereas a marker that remains constant error of tHcy measurement and CVD assessment. Possible specimen collection errors include failure to spin over a lifespan, such as the TT genotype, would not experience this relationship. within 30 minutes or a failure to refrigerate. This seems unlikely, since the mean levels are very similar to other Fifth, should the observation that dialysis patients with prevalent CVD have lower levels of tHcy than those studies. tHcy assessment was done using a commercial HPLC assay that is well established. With respect to without a history of CVD represent a refutation of the hypothesis that tHcy plays a role in vascular pathogeneusing clinical records for the assessment of CVD, we are likely overlooking cases of atherosclerotic disease in this sis? While this study is not designed to answer the question, it can lend credence to the assertion that tHcy population as most patients would have pathologic findings revealed by further clinical tests or autopsy.
represents a marker for other factors that are important in vascular pathophysiology, rather than a causative Third, there may be a strong nutritional component driving the relationship between tHcy and comorbidity agent. Not all epidemiologic studies in the general population and clinical studies in ESRD have supported an in ESRD due to the influence of serum albumin and dietary protein intake on tHcy levels. This observation association between homocysteine and CVD. Prospective case-cohort analyses from three large-scale commuis supported by similar findings in a recent cross-sectional study of 117 hemodialysis patients [16] . In that study, nity and population studies, The Atherosclerosis Risk in Communities Study [25] , a nine-year Finnish study tHcy levels were dependent on nutritional status, protein intake, and serum albumin, and patients with CVD had [26] , a report from the U.S. Physicians Health Study [27] , as well as a meta-analysis of 36 studies [6] have failed lower tHcy levels as well as a higher prevalence of malnutrition and hypoalbuminemia than those without CVD.
to find an association. Cross-sectional studies in ESRD have reported conflicting associations [10, 11, [28] [29] [30] , Furthermore, tHcy rises during treatment of malnourished patients with an amino acid-containing peritoneal and case-control studies may inflate an association by selection of non-ESRD controls [31] . A study of 73 dialysate (1.7 g methionine/day or half-normal intake) [17] . The presence of chronic inflammation further com-ESRD patients followed for 17 months was only able to adjust for one covariate at a time [32] . Another 17-month plicates the relationship by suppressing serum albumin, an important binding site for tHcy, and by contributing study of 167 patients with ESRD on dialysis found the relative risk for CVD to be 1.01 per 1 mol/L increase CVD. This description of this association is limited due to factors such as survivor bias, confounding by malnutriin tHcy, with a 95% confidence interval that included 1.00 [33] . Larger, prospective studies are needed in tion or inflammation as seen with other cardiovascular risk factors in ESRD, or the possibility that tHcy is not ESRD to address important questions about the causal role of homocysteine and clinical trials are needed in a causative risk factor in ESRD. THcy levels obtained after the onset of ESRD may not accurately represent both ESRD and the general population to establish tHcy as a modifiable risk factor. the lifetime tHcy exposure and the C677T genotype may be a more meaningful marker of abnormal homocysteine Previous studies have shown that the prevalence of the TT genotype remains stable across age groups in the metabolism in ESRD. Prospective data from ongoing clinical trials are needed to improve our understanding general population [34, 35] , and that the superior survival of African Americans and Asians compared with whites of this finding. in the United States has yet to be fully explained [36, 37] . Unlike some of these studies in the general population, ACKNOWLEDGMENTS our results support the assertion that the presence of the 
